Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, who is at least 18 years of age or older.~* A clinical diagnosis of rosacea.~* A Clinician Erythema Assessment (CEA) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1.~* A Patient Self Assessment-5 (PSA-5) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1.~* A Patient Self Assessment-11 (PSA-11) score of 5 at Screening and at Pre-dose (T0) on Baseline/Day 1.~Exclusion Criteria:~* Three (3) or more facial inflammatory lesions.~* Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.~* Known allergies or sensitivities to any components of the study medications, including the active gel ingredient, brimonidine tartrate.~* Intraocular pressure (IOP) measurement less than 10 mm Hg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD07805/47 Gel 0.5% QD (Type: EXPERIMENTAL): None
- CD07805/47 Gel 0.18% QD (Type: EXPERIMENTAL): None
- CD07805/47 Gel 0.18% BID (Type: EXPERIMENTAL): None
- Vehicle Gel QD (Type: PLACEBO_COMPARATOR): None
- Vehicle Gel BID (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).